CMP-5

Research use only, not for human use.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells; displays no activity against other type I (PRMT1 and PRMT4) and type II (PRMT7) enzymes; inhibition of PRMT5 leads to lost recruitment of a PRMT5/p65/HDAC3-repressive complex on the miR96 promoter, restored miR96 expression, and PRMT5 downregulation.

Western Blot Analysis Cell Line:60A cells?Concentration:40 μM Incubation Time:24 hours Result:Inhibited p-BTK and pY(416)SRC protein level.Cell Viability Assay Cell Line:Human Th1 cells and Th2 cells Concentration:25 μM Incubation Time:24 hours Result:Inhibited mouse Th1 cell proliferation, but addition of IL-2 dose-dependently increased cell proliferation.

——

PRMT5-IN-5

Chromatin/Epigenetic

HMTase

HMTase

——

——

880813-42-3

315.42

C21H21N3

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (396.31 mM)

CCN1C2=C(C=C(C=C2)CNCC3=CC=CC=N3)C4=CC=CC=C41.Cl

1-(9-Ethyl-9H-carbazol-3-yl)-N-(2-pyridinylmethyl)methanamine

(-20℃)

With Ice Pack

≥ 2 years